Trial Profile
Efficacy and Safety of Glimepiride as Oral Anti-Diabetic (OAD) Initiation Mono- Therapy in Chinese Type 2 Diabetes Mellitus (T2DM).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Aug 2012
Price :
$35
*
At a glance
- Drugs Glimepiride (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms GREAT
- Sponsors Sanofi
- 07 Aug 2012 Actual patient number changed from 392 to 391 as reported by ClinicalTrials.gov.
- 07 Aug 2012 Actual end date changed from Aug 2010 to Sep 2010 as reported by ClinicalTrials.gov.
- 07 Aug 2012 Actual initiation date changed from May 2009 to Apr 2009 as reported by ClinicalTrials.gov.